Compare Stocks: CABA, SNDX, LKFT, and AAPG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$18.90 -0.3%	$18.11	$16.36 ▼ $48.45	$1.77B	0.1	6,760 shs	2,980 shs
CABA Cabaletta Bio	$2.71 -4.9%	$2.91	$1.40 ▼ $4.23	$441.87M	3.3	3.72 million shs	3.08 million shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$28.04 +0.4%	$28.69	$25.68 ▼ $37.78	$1.85B	0.27	163,921 shs	379,801 shs
SNDX Syndax Pharmaceuticals	$19.08 -3.6%	$20.52	$12.99 ▼ $25.59	$1.69B	0.4	1.61 million shs	1.19 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+0.24%	+11.59%	-3.21%	-6.11%	-52.81%
CABA Cabaletta Bio	+2.15%	+5.17%	+2.89%	-21.05%	+114.29%
LKFT Lakefront Biotherapeutics American Depositary Shares	-2.78%	+7.09%	-6.28%	+1.60%	-11.81%
SNDX Syndax Pharmaceuticals	-2.41%	-0.60%	-13.50%	-3.65%	+52.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$18.90 -0.3%	$18.11	$16.36 ▼ $48.45	$1.77B	0.1	6,760 shs	2,980 shs
CABA Cabaletta Bio	$2.71 -4.9%	$2.91	$1.40 ▼ $4.23	$441.87M	3.3	3.72 million shs	3.08 million shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$28.04 +0.4%	$28.69	$25.68 ▼ $37.78	$1.85B	0.27	163,921 shs	379,801 shs
SNDX Syndax Pharmaceuticals	$19.08 -3.6%	$20.52	$12.99 ▼ $25.59	$1.69B	0.4	1.61 million shs	1.19 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+0.24%	+11.59%	-3.21%	-6.11%	-52.81%
CABA Cabaletta Bio	+2.15%	+5.17%	+2.89%	-21.05%	+114.29%
LKFT Lakefront Biotherapeutics American Depositary Shares	-2.78%	+7.09%	-6.28%	+1.60%	-11.81%
SNDX Syndax Pharmaceuticals	-2.41%	-0.60%	-13.50%	-3.65%	+52.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.20	Buy	$46.43	145.60% Upside
CABA Cabaletta Bio	2.57	Moderate Buy	$15.50	471.96% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.25	Hold	$30.67	9.37% Upside
SNDX Syndax Pharmaceuticals	2.85	Moderate Buy	$41.91	119.65% Upside

Current Analyst Ratings Breakdown

Latest CABA, SNDX, LKFT, and AAPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$30.00 ➝ $26.00
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$28.00 ➝ $26.00
8/11/2026	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
8/5/2026	SNDX Syndax Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $38.00
8/4/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/28/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	CABA Cabaletta Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
7/10/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Equal Weight	$30.00
6/24/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$82.10M	21.50	N/A	N/A	$2.04 per share	9.27
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.16 per share	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.47	$0.71 per share	39.57	$47.57 per share	0.59
SNDX Syndax Pharmaceuticals	$172.35M	9.81	N/A	N/A	$0.17 per share	112.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	-$167.86M	-$1.96	N/A	N/A	N/A	N/A	-131.58%	-96.46%	8/13/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	N/A

Latest CABA, SNDX, LKFT, and AAPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CABA Cabaletta Bio	-$0.3729	-$0.34	+$0.0329	-$0.34	$1.67 million	N/A
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.04	+$1.0072	$0.04	$7.29 million	$15.47 million
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million
5/14/2026	Q1 2026	CABA Cabaletta Bio	-$0.41	-$0.39	+$0.02	-$0.39	$1.67 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	0.57	1.79	1.77
CABA Cabaletta Bio	N/A	2.95	2.95
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	30.48	30.30
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
CABA Cabaletta Bio	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
CABA Cabaletta Bio	6.44%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
SNDX Syndax Pharmaceuticals	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	93.39 million	N/A	N/A
CABA Cabaletta Bio	50	163.05 million	152.55 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
SNDX Syndax Pharmaceuticals	110	88.61 million	84.36 million	Optionable

CABA, SNDX, LKFT, and AAPG Headlines

Recent News About These Companies

JPMorgan Chase & Co. Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

August 13 at 2:01 AM | americanbankingnews.com

Syndax (SNDX) Q2 2026 Earnings Call Transcript

August 11 at 11:49 PM | finance.yahoo.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co.

August 11 at 10:59 AM | marketbeat.com

Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX

August 9, 2026 | marketbeat.com

Q3 EPS Forecast for Syndax Pharmaceuticals Cut by Analyst

August 9, 2026 | americanbankingnews.com

How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors

August 8, 2026 | finance.yahoo.com

Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX

August 8, 2026 | marketbeat.com

HC Wainwright Brokers Decrease Earnings Estimates for SNDX

August 7, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

August 7, 2026 | americanbankingnews.com

What is HC Wainwright's Estimate for SNDX FY2029 Earnings?

August 6, 2026 | marketbeat.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 5, 2026 | globenewswire.com

Syndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 5, 2026 | seekingalpha.com

Syndax Pharmaceuticals (SNDX) Q2 2026

August 5, 2026 | 247wallst.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Disappointing Earnings

August 5, 2026 | marketbeat.com

HC Wainwright Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

August 5, 2026 | marketbeat.com

Sei Investments Co. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX

August 5, 2026 | marketbeat.com

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Syndax: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

Syndax Pharmaceuticals Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

August 4, 2026 | zacks.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results

August 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA, SNDX, LKFT, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$18.90 -0.07 (-0.35%)

Closing price 03:58 PM Eastern

Extended Trading

$18.90 +0.00 (+0.01%)

As of 04:10 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Cabaletta Bio NASDAQ:CABA

$2.71 -0.14 (-4.91%)

Closing price 04:00 PM Eastern

Extended Trading

$2.70 -0.01 (-0.37%)

As of 04:59 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$28.04 +0.11 (+0.39%)

As of 04:00 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Syndax Pharmaceuticals NASDAQ:SNDX

$19.08 -0.72 (-3.64%)

As of 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CABA, SNDX, LKFT, and AAPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CABA, SNDX, LKFT, and AAPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CABA, SNDX, LKFT, and AAPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA, SNDX, LKFT, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Cabaletta Bio NASDAQ:CABA

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CABA, SNDX, LKFT, and AAPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CABA, SNDX, LKFT, and AAPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CABA, SNDX, LKFT, and AAPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA, SNDX, LKFT, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Cabaletta Bio NASDAQ:CABA

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools